Drug Profile

APL 510

Alternative Names: APL-510; Melatonin modified release tablet - Alliance Pharmaceuticals

Latest Information Update: 12 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alliance Pharmaceuticals Limited
Class Anti-inflammatories; Chemoprotectants; Hormones; Radioprotectives; Sleep disorder therapies; Tryptamines
Mechanism of Action Melatonin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Sleep disorders

Most Recent Events

10 Oct 2022 No development reported - Phase-II for Sleep disorders (In adults) in United Kingdom (PO)
10 Oct 2005 Phase-II clinical trials in Sleep disorders (In adults) in United Kingdom (PO) (EudraCT2005-000120-17)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com